Honeywell International Inc vs Teladoc Health Inc — how do they compare? Honeywell International Inc trades at $229.58 (market cap $71.66B), while Teladoc Health Inc trades at $9.69 (market cap $1.74B). The key difference: Honeywell International Inc is far larger — about 41.2× Teladoc Health Inc's market cap, and Honeywell International Inc pays a 4.21% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| HON | TDOC | |
|---|---|---|
Market Cap | $71.66B | $1.74B |
Sector | Industrials | Health |
52-Week High | $248.04 | $9.72 |
52-Week Low | $188.14 | $4.47 |
Enterprise Value | $96.01B | $2.03B |
Dividend Yield | 4.21% | — |
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $229.86, up 2.15% with a bullish technical signal and strong analyst support. The company maintains solid profitability with 10.89% net margin and 26.41% ROE, though recent earnings show some pressure with Q2 2026 expectations at $1.80 EPS. Recent developments include a completed 2:1 reverse stock split and the acquisition of Johnson Matthey's Catalyst Technologies business for £1.325 billion, positioning the company for growth in automation and industrial technology.
HON presents a compelling investment case with 65% analyst buy ratings and a $368.55 consensus price target representing 60% upside. However, risks include declining profit margins (12.63% in 2025 vs 14.81% in 2024), increasing debt-to-asset ratio (46.65% in 2025), and near-term earnings uncertainty post-spinoffs. The stock's valuation at 18.07 P/E appears reasonable given its market leadership and strategic repositioning.
TDOC trades at $9.71, up 2.97% with a bullish technical signal. The stock shows improving fundamentals with revenue stabilizing around $2.5B and narrowing losses. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Positive sentiment is driven by partnerships like Walmart Better Care and cost-cutting initiatives, though net margins remain negative.
The outlook suggests cautious optimism as operational improvements may drive recovery, but persistent losses and high debt pose risks. Analyst consensus is mixed with 36% buy ratings and a $9.50 price target, indicating limited upside. Investors should weigh cost-control progress against competitive pressures in telehealth.
Trailing returns across standard periods
Latest headlines on both assets
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →